Russian eligibility criteria for menopausal hormone therapy in patients with cardiovascular and metabolic diseases

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Consensus document of the Russian Society of Cardiology, Russian Society of Obstetricians and Gynecologists, Russian Association of Endocrinologists, Eurasian Association of Therapists, Russian Phlebological Association.

Menopausal symptoms can significantly disrupt the lives of women who are at the peak of their careers and family life. Currently, menopausal hormone therapy (MHT) is the most effective approach to alleviate these symptoms. It is important to note that the presence of cardiovascular and metabolic diseases should not automatically rule out MHT in managing menopausal symptoms and enhancing overall quality of life. However, a common obstacle in the use of MHT is the fear of some physicians that it may do more harm than good to their patients. Caution should be exercised, especially in women with coexisting medical conditions. Furthermore, it is important to acknowledge the limited availability of high-quality research on the safety of MHT in the context of major chronic noncommunicable diseases and common comorbidities. This consensus document reviews all current data from clinical trials of various designs and provides a set of criteria for determining the suitability of MHT for women with cardiovascular and metabolic comorbidities. The aim of this document is to equip physicians from diverse specialties who care for menopausal women with an accessible algorithm that can help them avoid potentially risky situations and guide their decisions regarding prescribing menopausal hormone therapy in real-world practice

Full Text

Restricted Access

About the authors

Evgeny V. Shlyakhto

Almazov National Medical Research Centre, Ministry of Health of Russia

Email: info@scardio.ru
ORCID iD: 0000-0003-2929-0980

MD, PhD, Professor

Russian Federation, St. Petersburg

Gennady T. Sukhikh

Academician V.I. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia

Email: secretariat@oparina4.ru
ORCID iD: 0000-0002-7712-1260

Academician of RAS, MD, PhD, Professor

Russian Federation, Moscow

Vladimir N. Serov

Academician V.I. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia

Email: v_serov@oparina4.ru
ORCID iD: 0000-0003-2976-7128

Academician of RAS, MD, PhD, Professor

Russian Federation, Moscow

Ivan I. Dedov

National Medical Research Center for Endocrinology, Ministry of Health of Russia

Email: info@rae-org.ru
ORCID iD: 0000-0002-8175-7886

MD, PhD, Professor

Russian Federation, Moscow

Grigory P. Arutyunov

N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia

Email: arut@ossn.ru
ORCID iD: 0000-0002-6645-2515

MD, PhD, Professor

Russian Federation, Moscow

Igor A. Suchkov

Academician I.P. Pavlov Ryazan State Medical University, Ministry of Health of Russia

Email: suchkov_med@mail.ru

MD, PhD, Professor

Russian Federation, Ryazan

Yana A. Orlova

Lomonosov Moscow State University Medical Research and Education Center

Author for correspondence.
Email: 5163002@bk.ru
ORCID iD: 0000-0002-8160-5612

MD, PhD

Russian Federation, Moscow

Elena N. Andreeva

National Medical Research Center for Endocrinology, Ministry of Health of Russia; A.I. Yevdokimov Moscow State University of Medicine and Dentistry, Ministry of Health of Russia

Email: endogin@mail.ru
ORCID iD: 0000-0001-8425-0020
SPIN-code: 1239-2937

MD, PhD, Professor

 

Russian Federation, Moscow; Moscow

Svetlana V. Yureneva

Academician V.I. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia

Email: syureneva@gmail.com
ORCID iD: 0000-0003-2864-066X
SPIN-code: 3623-9149

MD, PhD, Professor

Russian Federation, Moscow

Igor S. Yavelov

National Medical Research Center for Therapy and Preventive Medicine, Ministry of Health of Russia

Email: yavelov@yahoo.com
ORCID iD: 0000-0003-2816-1183

MD, PhD, Professor

Russian Federation, Moscow

Maria I. Yarmolinskaya

D.O. Ott Research Institute for Obstetrics, Gynecology and Reproductology

Email: m.yarmolinskaya@gmail.com
ORCID iD: 0000-0002-6551-4147
SPIN-code: 3686-3605

MD, PhD, Professor

Russian Federation, St. Petersburg

Svetlana V. Villevalde

Almazov National Medical Research Centre, Ministry of Health of Russia

Email: villevaldes@mail.ru
ORCID iD: 0000-0001-7652-2962

MD, PhD, Professor

Russian Federation, St. Petersburg

Olga R. Grigoryan

National Medical Research Center for Endocrinology, Ministry of Health of Russia

Email: iceberg1995@mail.ru
ORCID iD: 0000-0003-4979-7420
SPIN-code: 3060-8242

MD, PhD, Professor

Russian Federation, Moscow

Ekaterina N. Dudinskaya

Russian Gerontology Research and Clinical Centre, Pirogov RNRMU, Ministry of Health of Russia

Email: katharina.gin@gmail.com
ORCID iD: 0000-0001-7891-6850

MD, PhD

Russian Federation, Moscow

Evgeniy A. Ilyukhin

Medalp LLC

Email: iluhin-e@yandex.ru

PhD

Russian Federation, St. Petersburg

Natalya A. Koziolova

Academician E.A. Wagner Perm State Medical University, Ministry of Health of Russia

Email: nakoziolova@mail.ru
ORCID iD: 0000-0001-7003-5186

MD, PhD, Professor

 

Russian Federation, Perm

Igor V. Sergienko

Academician E.I. Chazov National Medical Research Center for Cardiology, Ministry of Health of Russia

Email: gorcardio@mail.ru
ORCID iD: 0000-0003-1534-3965

MD, PhD, Professor

Russian Federation, Moscow

Antonina A. Smetnik

Academician V.I. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia

Email: asmetnik@gmail.com
ORCID iD: 0000-0002-0627-3902

PhD

Russian Federation, Moscow

Natalya I. Tapilskaya

D.O. Ott Research Institute for Obstetrics, Gynecology and Reproductology

Email: tapnatalia@yandex.ru
ORCID iD: 0000-0001-5309-0087

MD, PhD, Professor

Russian Federation, St. Petersburg

References

  1. Распоряжение Правительства Российской Федерации от 29 декабря 2022 г. N 4356-р «Об утверждении Национальной стратегии действий в интересах женщин на 2023–2030 годы». Доступно на: https://www.consultant.ru/document/cons_doc_LAW_436691. [Decree of the Government of the Russian Federation No. 4356-р dated Dec 29, 2022 “On the approval of the National Strategy for Action in the Interests of Women for 2023–2030”. Available at: https://www.consultant.ru/document/ cons_doc_LAW_436691 (in Russian)].
  2. Улумбекова Г.Э., Худова И.Ю. Оценка демографического, социального и экономического эффекта при приеме менопаузальной гормональной терапии. ОРГЗДРАВ: новости, мнения. Вестник ВШОУЗ. 2020; 6(4(22)): 23-53. [Ulumbekova GE, Khudova IYu. Demographic, social and economic effects of menopause hormonal therapy. Healthcare management: News, Views, Education. Bulletin of VSHOUZ. 2020;6(4(22)):23-53. (in Russian)]. https://doi.org/10.24411/2411-8621-2020-14002
  3. Lambrinoudaki I, Armeni E, Goulis D, Bretz S, Ceausu I, Durmusoglu F et al. Menopause, wellbeing and health: A care pathway from the European Menopause and Andropause Society. Maturitas. 2022;163:1-14. https://doi.org/10.1016/j.maturitas.2022.04.008
  4. Министерство здравоохранения Российской Федерации. Клинические рекомендации. Менопауза и климактерическое состояние у женщины. М.: 2021. Доступно на: https://cr.minzdrav.gov.ru/recomend/117_2 [Ministry of Health of the Russian Federation. Clinical Guidelines. Menopause and female climacteric states. 2021. Available at: https://cr.minzdrav.gov.ru/recomend/117_2 (in Russian)].
  5. Harlow SD, Gass M, Hall JE, Lobo R, Maki P, Rebar RW et al. Executive summary of the Stages of Reproductive Aging Work- shop + 10: addressing the unfinished agenda of staging reproductive aging. Menopause. 2012; 19(4):387-95. https://doi.org/10.1097/ gme.0b013e31824d8f40
  6. Drewe J, Bucher KA, Zahner C. A systematic review of non-hormonal treatments of vasomotor symptoms in climacteric and cancer patients. SpringerPlus. 2015;4(1):65. https://doi.org/10.1186/s40064-015-0808-y
  7. Schnatz PF, Romegialli A, Abrantes J, Marakovits K, Cunningham D, O’Sullivan DM. The North American Menopause Society: from abstract to publication. Menopause. 2008;15(5):996-1001 https://doi.org/10.1097/gme.0b013e318166f026
  8. Paramsothy P, Harlow SD, Nan B, Greendale GA, Santoro N, Craw- ford SL et al. Duration of the menopausal transition is longer in wom- en with young age at onset: the multiethnic Study of Women’s Health Across the Nation. Menopause. 2017;24(2):142-9. https://doi.org/10.1097/ GME.0000000000000736
  9. Сухих Г.Т., Сметник В.П., Андреева Е.Н., Балан В.Е., Гависова А.А., Григорян О.Р. и др. Менопаузальная гормонотерапия и сохранение здоровья женщин в зрелом возрасте. Клинические рекомендации. 2015. Доступно на: https://www.consultant.ru/document/cons_doc_LAW_320073/ [Sukhih G.T., Smetnik V.P., Andreeva E.N., Balan V.E., Gavisova A.A., Grigoryan O.R. et al. Menopausal hormone therapy and maintaining the health of women in adulthood. Clinical Guidelines. 2015. Available at: https://www.consultant.ru/document/cons_doc_ LAW_320073/ (in Russian)].
  10. Schoenaker DA, Jackson CA, Rowlands JV, Mishra GD. Socioeco- nomic position, lifestyle factors and age at natural menopause: a sys- tematic review and meta-analyses of studies across six continents. In- ternational Journal of Epidemiology. 2014;43(5):1542-62. https://doi.org/10.1093/ije/dyu094
  11. Freeman EW, Sammel MD, Sanders RJ. Risk of long-term hot flash- es after natural menopause: evidence from the Penn Ovarian Aging Study cohort. Menopause. 2014;21(9):924-32. https://doi.org/10.1097/ GME.0000000000000196
  12. Costanian C, Zangiabadi S, Bahous SA, Deonandan R, Tamim H. Re viewing the evidence on vasomotor symptoms: the role of traditional and non-traditional factors. Climacteric. 2020;23(3):213-23. https://doi.org/10.1080/ 13697137.2019.1711051
  13. Prior JC. Progesterone for Symptomatic Perimenopause Treatment - Progesterone politics, physiology and potential for perimenopause. Facts, Views & Vision in ObGyn. 2011;3(2):109-20. PMID: 24753856
  14. Santoro N, Epperson CN, Mathews SB. Menopausal Symptoms and Their Management. Endocrinology and Metabolism Clinics of North America. 2015;44(3):497-515. https://doi.org/10.1016/j. ecl.2015.05.001
  15. Мельниченко Г.А., Белая Ж.Е., Рожинская Л.Я., Торопцова Н.В., Алексеева Л.И., Бирюкова Е.В. и др. Федеральные клинические рекомендации по диагностике, лечению и профилактике остеопороза. Проблемы эндокринологии. 2017;63(6):392-426. [Mel’nichenko G.A., Belaya J.E., Rozhinskaya L.Ya., Toroptsova N.V., Alekseeva L.I., Biryukova E.V. et al. Russian federal clinical guidelines on the diagnostics, treatment, and prevention of osteoporosis. Problems of Endocrinology. 2018;63(6):392-426. (in [Russian)]. https://doi.org/10.14341/probl2017636392-426
  16. Muka T, Oliver-Williams C, Colpani V, Kunutsor S, Chowdhury S, Chowdhury R et al. Association of Vasomotor and Other Menopausal Symptoms with Risk of Cardiovascular Disease: A Systematic Review and Meta-Analysis. PLOS One. 2016;11(6):e0157417. https://doi.org/10.1371/ journal.pone.0157417
  17. Baber RJ, Panay N, Fenton A. 2016 IMS Recommendations on women’s midlife health and menopause hormone therapy. Climacteric. 2016;19(2):109-50. https://doi.org/10.3109/13697137.2015.1129166
  18. Hirschberg AL, Bitzer J, Cano A, Ceausu I, Chedraui P, Durmusoglu F et al. Topical estrogens and non-hormonal preparations for postmenopausal vulvovaginal atrophy: An EMAS clinical guide. Maturitas. 2021;148:55-61. https://doi.org/10.1016/j.maturitas.2021.04.005
  19. Grundy SM. Metabolic Syndrome: A Multiplex Cardiovascular Risk Factor. The Journal of Clinical Endocrinology & Metabolism. 2007;92(2):399-404 https://doi.org/10.1210/jc.2006-0513
  20. Hu G, The DECODE Study Group. Gender difference in all-cause and cardiovascular mortality related to hyperglycaemia and newly-diagnosed diabetes. Diabetologia. 2003;46(5):608-17. https://doi.org/10.1007/ s00125-003-1096-6
  21. Vishram JKK, Borglykke A, Andreasen AH, Jeppesen J, Ibsen H, Jørgensen T et al. Impact of Age and Gender on the Prevalence and Prognostic Importance of the Metabolic Syndrome and Its Components in Europeans. The MORGAM Prospective Cohort Project. PLoS One. 2014;9(9):e107294. https://doi.org/10.1371/journal. pone.0107294
  22. Драпкина О.М., Концевая А.В., Калинина А.М., Авдеев С.Н., Агальцов М.В. и др. Профилактика хронических неинфекционных заболеваний в Российской Федерации. Национальное руководство 2022. Кардиоваскулярная терапия и профилактика. 2022;21(4):5-232. [Drapkina O.M., Kontsevaya A.V., Kalinina A.M., Avdeev S.M., Agaltsov M.V., Alexandrova L.M. et al. 2022 Prevention of chronic non-communicable diseases in the Russian Federation. National guidelines. Cardiovascular Therapy and Prevention. 2022;21(4):5-232. (in Russian)]. https://doi.org/10.15829/1728-8800- 2022-3235
  23. Cushman M. Estrogen Plus Progestin and Risk of Venous Thrombosis. JAMA. 2004;292(13):1573-80. https://doi.org/10.1001/jama.292.13.1573
  24. Трошина Е.А., Покусаева В.Н., Андреева Е.Н., Григорян О.Р., Мазурина Н.В., Дзгоева Ф.Х. и др. Ожирение у женщин. [Григорян О.Р., Андреева Е.Н. Ожирение и менопауза. С.233-268]. М.: Медицинское информационное агентство; 2017. 272c. [Troshina E.N., Pokusayeva V.N., Andreeva E.N., Grigoryan O.R., Ma-zurina N.V., Dzgoeva F.H. et al. Obesity among women. [Grigoryan O.R., Andreeva E.N. Obesity and menopause. P. 233-268]. M.: Medical Information Agency; 2017. 272 p. (in Russian)]. ISBN 978-5-9986-0296-2
  25. Caprio M, Antelmi A, Chetrite G, Muscat A, Mammi C, Marzolla V et al. Antiadipogenic Effects of the Mineralocorticoid Receptor Antagonist Drospirenone: Potential Implications for the Treatment of Metabolic Syndrome. Endocrinology. 2011;152(1):113-25. https://doi.org/10.1210/en.2010-0674
  26. Rizzo MR, Leo S, De Franciscis P, Colacurci N, Paolisso G. Short-term effects of low-dose estrogen/drospirenone vs low-dose estrogen/ dydrogesterone on glycemic fluctuations in postmenopausal women with metabolic syndrome. AGE. 2014;36(1):265-74. https://doi.org/10.1007/ s11357-013-9554-7
  27. Дедов И.И., Шестакова М.В., Викулова О.К., Железнякова А.В., Исаков М.А. Эпидемиологические характеристики сахарного диабета в Российской Федерации: клинико-статистический анализ по данным регистра сахарного диабета на 01.01.2021. Сахарный диабет. 2021;24(3):204-21. [Dedov I.I., Shestakova M.V., Vikulova O.K., Zheleznyakova A.V., Isakov M.A. Epidemiological characteristics of diabetes mellitus in the Russian Federation: clinical and statistical analysis according to the Federal diabetes register data of 01.01.2021. Diabetes mellitus. 2021;24(3):204-21. (in Russian)]. https://doi.org/10.14341/DM12759
  28. Manson JE, Chlebowski RT, Stefanick ML, Aragaki AK, Rossouw JE, Prentice RL et al. Menopausal Hormone Therapy and Health Outcomes During the Intervention and Extended Poststopping Phases of the Women’s Health Initiative Randomized Trials. JAMA. 2013;310(13):1353-68. https://doi.org/10.1001/jama.2013.278040
  29. Salpeter SR, Walsh JME, Ormiston TM, Greyber E, Buckley NS, Salpeter EE. Meta‐analysis: effect of hormone‐replacement thera py on components of the metabolic syndrome in postmenopausal women. Diabetes, Obesity and Metabolism. 2006;8(5):538-54. https://doi.org/10.1111/ j.1463-1326.2005.00545.x
  30. Grigoryan O.R. Climacteric syndrome in women with diabetes mel litus. Diabetes Mellitus. 2013;16(3):103-8. https://doi.org/10.14341/2072- 0351-824
  31. Mendoza N, Ramírez I, De La Viuda E, Coronado P, Baquedano L, Llaneza P et al. Eligibility criteria for Menopausal Hormone Therapy (MHT): a position statement from a consortium of scientific societies for the use of MHT in women with medical conditions. MHT Eligibility Criteria Group. Maturitas. 2022;166:65-85. https://doi.org/10.1016/j.maturitas.2022.08.008
  32. Kim J-E, Chang J-H, Jeong M-J, Choi J, Park J, Baek C et al. A systematic review and meta-analysis of effects of menopausal hormone therapy on cardiovascular diseases. Scientific Reports. 2020;10(1):20631. https://doi.org/10.1038/ s41598-020-77534-9
  33. Boardman HM, Hartley L, Eisinga A, Main C, Roqué I Figuls M, Bon fill Cosp X et al. Hormone therapy for preventing cardiovascular disease in post-menopausal women. Cochrane Database of Systematic Reviews. 2015;2015(8):CD002229. https://doi.org/10.1002/14651858. CD002229.pub4
  34. Vinogradova Y, Coupland C, Hippisley-Cox J. Use of hormone re- placement therapy and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases. BMJ. 2019;364:k4810. https://doi.org/10.1136/bmj.k4810
  35. Goldštajn MŠ, Mikuš M, Ferrari FA, Bosco M, Uccella S, Noventa M et al. Effects of transdermal versus oral hormone replacement therapy in postmenopause: a systematic review. Archives of Gynecology and Obstetrics. 2022;307(6):1727-45. https://doi.org/10.1007/s00404-022- 06647-5
  36. Kapoor E, Kling JM, Lobo AS, Faubion SS. Menopausal hormone therapy in women with medical conditions. Best Practice & Research Clinical Endocrinology & Metabolism. 2021;35(6):101578. https://doi.org/10.1016/ j.beem.2021.101578
  37. Morris G, Talaulikar V. Hormone replacement therapy in women with history of thrombosis or a thrombophilia. Post Reproductive Health. 2023;29(1):33-41. https://doi.org/10.1177/20533691221148036
  38. Blondon M, Timmons AK, Baraff AJ, Floyd JS, Harrington LB, Korpak AM et al. Comparative venous thromboembolic safety of oral and transdermal postmenopausal hormone therapies among women Veterans. Menopause. 2021;28(10):1125-9. https://doi.org/10.1097/ GME.0000000000001823
  39. Sobel TH, Shen W. Transdermal estrogen therapy in meno- pausal women at increased risk for thrombotic events: a scoping review. Menopause. 2022;29(4):483-90. DOI: 10.1097/ GME.0000000000001938
  40. The 2022 hormone therapy position statement of The North American Menopause Society. Menopause. 2022;29(7):767-94. https://doi.org/10.1097/GME.0000000000002028
  41. Dinger J, Bardenheuer K, Heinemann K. Drospirenone plus es- tradiol and the risk of serious cardiovascular events in post-menopausal women. Climacteric. 2016;19(4):349-56. https://doi.org/10.1080/13697137.2016.1183624
  42. Tepper NK, Whiteman MK, Marchbanks PA, James AH, Curtis KM. Progestin-only contraception and thromboembolism: A systematic review. Contraception. 2016;94(6):678-700. https://doi.org/10.1016/j.contraception.2016.04.014
  43. Mantha S, Karp R, Raghavan V, Terrin N, Bauer KA, Zwicker JI. Assessing the risk of venous thromboembolic events in women taking progestin-only contraception: a meta-analysis. BMJ. 2012;345:e4944. https://doi.org/ 10.1136/bmj.e4944
  44. Nudy M, Chinchilli VM, Foy AJ. A systematic review and meta-regression analysis to examine the ‘timing hypothesis’ of hormone replacement therapy on mortality, coronary heart disease, and stroke. IJC Heart & Vasculature. 2019;22:123-31. https://doi.org/10.1016/j.ijcha.2019.01.001
  45. Cho L, Kaunitz AM, Faubion SS, Hayes SN, Lau ES, Pristera N et al. Rethinking Menopausal Hormone Therapy: For Whom, What, When, and How Long? Circulation. 2023;147(7):597-610. https://doi.org/10.1161/ CIRCULATIONAHA.122.061559
  46. LaVasseur C, Neukam S, Kartika T, Samuelson Bannow B, Shatzel J, DeLoughery TG. Hormonal therapies and venous thrombosis: Con- siderations for prevention and management. Research and Practice in Thrombosis and Haemostasis. 2022;6(6):e12763. https://doi.org/10.1002/ rth2.12763
  47. Roach REJ, Lijfering WM, Van Hylckama Vlieg A, Helmerhorst FM, Rosendaal FR, Cannegieter SC. The risk of venous thrombosis in in- dividuals with a history of superficial vein thrombosis and acquired venous thrombotic risk factors. Blood. 2013;122(26):4264-9. https://doi.org/10.1182/ blood-2013-07-518159
  48. Douketis JD, Julian JA, Crowther MA, Kearon C, Bates SM, Ba- rone M et al. The Effect of Prothrombotic Blood Abnormalities on Risk of Deep Vein Thrombosis in Users of Hormone Replace- ment Therapy: A Prospective Case-Control Study. Clinical and Applied Thrombosis/Hemostasis. 2011;17(6):E106-13. https://doi.org/10.1177/1076029610387587
  49. Straczek C, Oger E, Yon De Jonage-Canonico MB, Plu-Bureau G, Conard J, Meyer G et al. Prothrombotic Mutations, Hormone Therapy, and Venous Thromboembolism Among Postmenopau- sal Women: Impact of the Route of Estrogen Administration. Circulation. 2005;112(22):3495-500. https://doi.org/10.1161/CIRCULA- TIONAHA.105.565556
  50. Bezemer ID, Van Der Meer FJM, Eikenboom JCJ, Rosendaal FR, Doggen CJM. The Value of Family History as a Risk Indicator for Venous Thrombosis. Archives of Internal Medicine. 2009;169(6):610-5. https://doi.org/10.1001/archinternmed.2008.589
  51. Brighouse D. Hormone replacement therapy (HRT) and anaesthesia. British Journal of Anaesthesia. 2001;86(5):709-16. https://doi.org/10.1093/ bja/86.5.709
  52. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B et al. Randomized Trial of Estrogen Plus Progestin for Secondary Prevention of Coronary Heart Disease in Postmenopausal Women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA. 1998;280(7):605-13. https://doi.org/10.1001/jama.280.7.605
  53. Wassertheil-Smoller S, Hendrix S, Limacher M, Heiss G, Kooper- berg C, Baird A et al. Effect of Estrogen Plus Progestin on Stroke in Postmenopausal Women: The Women’s Health Initiative: A Randomized Trial. JAMA. 2003;289(20):2673-84. https://doi.org/10.1001/ja- ma.289.20.2673
  54. Hendrix SL, Wassertheil-Smoller S, Johnson KC, Howard BV, Kooperberg C, Rossouw JE et al. Effects of Conjugated Equine Estrogen on Stroke in the Women’s Health Initiative. Circu- lation. 2006;113(20):2425-34. https://doi.org/10.1161/CIRCULATIONAHA.105.594077
  55. The 2020 genitourinary syndrome of menopause position state- ment of The North American Menopause Society. Menopause. 2020;27(9):976-92. https://doi.org/10.1097/GME.0000000000001609
  56. Te West NID, Day RO, Hiley B, White C, Wright M, Moore KH. Es- triol serum levels in new and chronic users of vaginal estriol cream: A prospective observational study. Neurourology and Urodynamics. 2020;39(4):1137-44. https://doi.org/10.1002/nau.24331
  57. Santen RJ, Mirkin S, Bernick B, Constantine GD. Systemic estradiol levels with low-dose vaginal estrogens. Menopause. 2020;27(3):361- 70. https://doi.org/10.1097/GME.0000000000001463
  58. Bhupathiraju SN, Grodstein F, Stampfer MJ, Willett WC, Crandall CJ, Shifren JL et al. Vaginal estrogen use and chronic disease risk in the Nurses’ Health Study. Menopause. 2019;26(6):603-10. https://doi.org/10.1097/GME.0000000000001284
  59. Crandall CJ, Hovey KM, Andrews CA, Chlebowski RT, Stefanick ML, Lane DS et al. Breast cancer, endometrial cancer, and cardiovascular events in participants who used vaginal estrogen in the Womens Health Initiative Observational Study. Menopause. 2018;25(1):11-20. https://doi.org/10.1097/GME.0000000000000956
  60. Орлова Я.А., Плисюк А.Г., Долгушин Г.О., Кириллова К.И., Михеев Р.К., Андреева Е.Н. Связь длительной менопаузальной гормональной терапии и показателей сосудистого и репликативного старения у женщин. Профилактическая медицина. 2023;26(7):96-102. [Orlova Ya.A., Plisyuk A.G., Dolgushin G.O., Kirillova K.I., Mikheev R.K., Andreeva E.N. Correlation between prolonged meno- pausal hormonotherapy and indicators of vascular and replicative aging in women. Prevention Medicine. 2023;26(7): 96-102. (in Russian)]. https://doi.org/10.17116/profmed20232607196
  61. Draper MW, Flowers DE, Huster WJ, Neild JA, Harper KD, Arnaud C. A controlled trial of raloxifene (LY139481) HCl: Impact on bone turnover and serum lipid profile in healthy postmenopausal women. Journal of Bone and Mineral Research. 2009;11(6):835-42. https://doi.org/10.1002/jbmr.5650110615
  62. Nie G, Yang X, Wang Y, Liang W, Li X, Luo Q et al. The Effects of Menopause Hormone Therapy on Lipid Profile in Postmenopausal Women: A Systematic Review and Meta-Analysis. Frontiers in Pharmacology. 2022;13:850815. https://doi.org/10.3389/fphar.2022.850815
  63. Ежов М.В., Кухарчук В.В., Сергиенко И.В., Алиева А.С., Анциферов М.Б., Аншелес А.А. и др. Нарушения липидного обмена. Клинические рекомендации 2023. Российский кардиологический журнал. 2023;28(5):250-97. [Ezhov M.V., Kukharchuk V.V., Sergienko I.V., Alieva A.S., An- tsiferov M.B., Ansheles A.A. et al. Disorders of lipid metabo- lism. Clinical Guidelines 2023. Russian Journal of Cardiology. 2023;28(5):250-97. (in Russian)]. https://doi.org/10.15829/1560-4071-2023-5471
  64. Nordestgaard BG, Chapman MJ, Ray K, Borén J, Andreotti F, Watts GF et al. Lipoprotein(a) as a cardiovascular risk factor: current status. European Heart Journal. 2010;31(23):2844-53. https://doi.org/10.1093/eurheartj/ehq386
  65. Van Dam-Nolen DHK, Van Dijk AC, Crombag GAJC, Lucci C, Kooi ME, Hendrikse J et al. Lipoprotein(a) levels and atherosclerotic plaque characteristics in the carotid artery: The Plaque at RISK (PARISK) study. Atherosclerosis. 2021;329:22-9. https://doi.org/10.1016/ j. atherosclerosis.2021.06.004
  66. Stevenson JC, Chines A, Pan K, Ryan KA, Mirkin S. A Pooled Anal- ysis of the Effects of Conjugated Estrogens/Bazedoxifene on Lipid Parameters in Postmenopausal Women From the Selective Estrogens, Menopause, and Response to Therapy (SMART) Trials. The Journal of Clinical Endocrinology & Metabolism. 2015;100(6):2329-38. https://doi.org/10.1210/ jc.2014-2649
  67. Miller VT, LaRosa J, Barnabei V, Kessler C, Levin G, Smith-Roth A et al. Effects of Estrogen or Estrogen/ Progestin Regimens on Heart Disease Risk Factors in Postmenopausal Women: The Postmeno- pausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA. 1995;273(3):199-208. https://doi.org/10.1001/jama.1995.03520270033028
  68. Binder EF, Birge SJ, Kohrt WM. Effects of Endurance Exercise and Hormone Replacement Therapy on Serum Lipids in Older Women. Journal of the American Geriatrics Society. 1996;44(3):231-6. https://doi.org/10.1111/ j.1532-5415.1996.tb00907.x
  69. Bunyavejchevin S, Limpaphayom KK. The metabolic and bone density effects of continuous combined 17-beta estradiol and noresthisterone acetate treatments in Thai postmenopausal women: a double- blind placebo-controlled trial. Journal of the Medical Association of Thailand. 2001;84(1):45-53. PMID: 11281499
  70. Çayan F, Gen R, Akbay E, Dilek U, Dilek S. The Effect of Hor- mone Therapy and Tibolone on Glucose and Lipid Metabolism in Healthy Postmenopausal Women. Turkish Journal of Geriatrics. 2011;14(1):19-25. Available at: https://geriatri.dergisi.org/abstract. php?id=534
  71. Cheng GJ, Liu JL, Zhang Q, Fan W, Ye HF, Wang ZQ et al. Nylestriol replacement therapy in postmenopausal women. A three-year prospective study. Chinese Medical Journal. 1993;106(12):911-6. PMID: 8198628
  72. Conard J, Basdevant A, Thomas J-L, Ochsenbein E, Denis C, Guy- ene TT et al. Cardiovascular risk factors and combined estrogen-progestin replacement therapy: a placebo-controlled study with nomege trol acetate and estradiol. Fertility and Sterility. 1995;64(5):957-62. https://doi.org/10.1016/ S0015-0282(16)57909-6
  73. Conard J, Gompel A, Pelissier C, Mirabel C, Basdevant A. Fibrino- gen and plasminogen modifications during oral estradiol replacement therapy. Fertility and Sterility. 1997;68(3):449-53. https://doi.org/10.1016/ S0015-0282(97)00220-3
  74. Davidson MH, Maki KC, Marx P, Maki AC, Cyrowski MS, Nanavati N et al. Effects of Continuous Estrogen and Estrogen-Progestin Replacement Regimens on Cardiovascular Risk Markers in Postmenopausal Wom- en. Archives of Internal Medicine. 2000;160(21):3315-25. https://doi.org/10.1001/ archinte.160.21.3315
  75. Duvernoy CS, Rose PA, Kim HM, Kehrer C, Brook RD. Combined Con- tinuous Ethinyl Estradiol/Norethindrone Acetate Does Not Improve Forearm Blood Flow in Postmenopausal Women at Risk for Cardiovascular Events: A Pilot Study. Journal of Women’s Health. 2007;16(7):963-70. https://doi.org/10.1089/jwh.2006.0321
  76. Casanova G, Dos Reis AM, Spritzer PM. Low-dose oral or non-oral hormone therapy: effects on C-reactive protein and atrial natriuretic peptide in menopause. Climacteric. 2015;18(1):86-93. https://doi.org/10.3109/13697137.2014.940309
  77. Haase CL, Tybjærg-Hansen A, Ali Qayyum A, Schou J, Nordestgaard BG, Frikke-Schmidt R. LCAT, HDL Cholesterol and Ischemic Cardiovascu- lar Disease: A Mendelian Randomization Study of HDL Cholesterol in 54,500 Individuals. The Journal of Clinical Endocrinology & Metabolism. 2012;97(2):E248-56. https://doi.org/10.1210/jc.2011-1846
  78. Lv C, Zhang W, Tan X, Shang X, Găman M-A, Salem H et al. The effect of tibolone treatment on lipid profile in women: A systematic review and dose-response meta-analysis of randomized controlled trials. Pharmacolog ical Research. 2021;169:105612. https://doi.org/10.1016/j.phrs.2021.105612
  79. Anagnostis P, Galanis P, Chatzistergiou V, Stevenson JC, Godsland IF, Lam- brinoudaki I et al. The effect of hormone replacement therapy and tibolone on lipoprotein (a) concentrations in postmenopausal women: A systematic review and meta-analysis. Maturitas. 2017;99:27-36. https://doi.org/10.1016/ j.maturitas.2017.02.009
  80. Falkeborn M, Persson I, Adami H-O, Bergstrom R, Eaker E, Lithell H et al. The risk of acute myocardial infarction after oestrogen and oestrogen- progestogen replacement. British Journal of Obstetrics and Gynaecology. 1992;99(10):821-8. https://doi.org/10.1111/j.1471-0528.1992.tb14414.x
  81. Shufelt CL, Manson JE. Menopausal Hormone Therapy and Cardiovas- cular Disease: The Role of Formulation, Dose, and Route of Delivery. The Journal of Clinical Endocrinology & Metabolism. 2021;106(5):1245-54. https://doi.org/10.1210/clinem/dgab042
  82. Anagnostis P, Bitzer J, Cano A, Ceausu I, Chedraui P, Durmusoglu F et al. Menopause symptom management in women with dyslipidemias: An EMAS clinical guide. Maturitas. 2020;135:82-8 https://doi.org/10.1016/ j.maturitas.2020.03.007
  83. Wenger NK, Lloyd-Jones DM, Elkind MSV, Fonarow GC, Warner JJ, Al- ger HM et al. Call to Action for Cardiovascular Disease in Women: Epi- demiology, Awareness, Access, and Delivery of Equitable Health Care: A Presidential Advisory From the American Heart Association. Circulation. 2022;145(23):e1059-71. https://doi.org/10.1161/CIR.0000000000001071
  84. Vogel B, Acevedo M, Appelman Y, Bairey Merz CN, Chieffo A, Figtree GA et al. The Lancet women and cardiovascular disease Commission: reducing the global burden by 2030. The Lancet. 2021;397(10292):2385-438. https://doi.org/10.1016/S0140-6736(21)00684-X
  85. Reckelhoff JF. Gender differences in hypertension: Current Opinion in Nephrology and Hypertension. 2018;27:176-81. https://doi.org/10.1097/ MNH.0000000000000404
  86. Cho L, Davis M, Elgendy I, Epps K, Lindley KJ, Mehta PK et al. Summary of Updated Recommendations for Primary Prevention of Cardiovascular Disease in Women. Journal of the American College of Cardiology. 2020;75(20):2602-18. https://doi.org/10.1016/j.jacc.2020.03.060
  87. Gerdts E, Sudano I, Brouwers S, Borghi C, Bruno RM, Ceconi C et al. Sex differences in arterial hypertension. European Heart Journal. 2022;43(46):4777-88. https://doi.org/10.1093/eurheartj/ehac470
  88. Zhou B, Carrillo-Larco RM, Danaei G, Riley LM, Paciorek CJ, Stevens GA et al. Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 pop ulation-representative studies with 104 million participants. The Lancet. 2021;398(10304):957-80. https://doi.org/10.1016/S0140-6736(21)01330-1
  89. O’Keeffe LM, Simpkin AJ, Tilling K, Anderson EL, Hughes AD, Lawlor DA et al. Sex-specific trajectories of measures of cardiovascular health during childhood and adolescence: A prospective cohort study. Atherosclerosis. 2018;278:190-6. https://doi.org/10.1016/j.atherosclerosis.2018.09.030
  90. Ji H, Kim A, Ebinger JE, Niiranen TJ, Claggett BL, Bairey Merz CN et al. Sex Differences in Blood Pressure Trajectories Over the Life Course. JAMA Cardiology. 2020;5(3):19-26. https://doi.org/10.1001/jamacardio.2019.5306
  91. Maas A, Rosano G, Cifkova R, Chieffo A, Van Dijken D, Hamoda H et al. Cardiovascular health after menopause transition, pregnancy disorders, and other gynaecologic conditions: a consensus document from European cardiologists, gynaecologists, and endocrinologists. European Heart Jour nal. 2021;42(10):967-84. https://doi.org/10.1093/eurheartj/ehaa1044
  92. El Khoudary SR, Aggarwal B, Beckie TM, Hodis HN, Johnson AE, Langer RD et al. Menopause Transition and Cardiovascular Disease Risk: Implications for Timing of Early Prevention: A Scientific Statement From the American Heart Association. Circulation. 2020;142(25):e506-32. https://doi.org/10.1161/CIR.0000000000000912
  93. Biglia N, Cagnacci A, Gambacciani M, Lello S, Maffei S, Nappi RE. Va- somotor symptoms in menopause: a biomarker of cardiovascular disease risk and other chronic diseases? Climacteric. 2017;20(4):306-12. https://doi.org/10.1080/13697137.2017.1315089
  94. Chapman N, Ching SM, Konradi AO, Nuyt AM, Khan T, Twumasi-Ankrah B et al. Arterial Hypertension in Women: State of the Art and Knowledge Gaps. Hypertension. 2023;80(6):1140-9. https://doi.org/10.1161/HYPERTEN- SIONAHA.122.20448
  95. Coutinho T. Arterial Stiffness and Its Clinical Implications in Women. Ca- nadian Journal of Cardiology. 2014;30(7):756-64. doi: 10.1016/j.cj- ca.2014.03.020
  96. Picone DS, Kodithuwakku V, Mayer CC, Chapman N, Rehman S, Clim- ie RE. Sex differences in pressure and flow waveform physiology across the life course. Journal of Hypertension. 2022;40(12):2373-84. doi: 10.1097/HJH.0000000000003283
  97. Mosca L, Benjamin EJ, Berra K, Bezanson JL, Dolor RJ, Lloyd- Jones DM et al. Effectiveness-Based Guidelines for the Prevention of Cardiovascular Disease in Women-2011 Update: A Guideline From the American Heart Association. Circulation. 2011;123(11):1243-62. https://doi.org/10.1161/ CIR.0b013e31820faaf8
  98. Issa Z, Seely EW, Rahme M, El-Hajj Fuleihan G. Effects of hormone ther apy on blood pressure. Menopause. 2015;22(4):456-68. https://doi.org/10.1097/ GME.0000000000000322
  99. Mancia G, Kreutz R, Brunström M, Burnier M, Grassi G, Januszewicz A et al. 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). Journal of Hypertension. 2023; [Epub ahead of print]. https://doi.org/10.1097/ HJH.0000000000003480
  100. Кобалава Ж.Д., Конради А.О., Недогода С.В., Шляхто Е.В., Арутюнов Г.П., Баранова Е.И. и др. Артериальная гипертензия у взрослых. Клинические рекомендации 2020. Российский кардиологический журнал. 2020;25(3):149-218. [Kobalava Zh.D., Konradi A.O., Nedogoda S.V., Shlyakhto E.V., Aru- tyunov G.P., Baranova E.I. et al. Arterial hypertension in adults. Clinical guidelines 2020. Russian Journal of Cardiology. 2020; 25(3):149-218. (in Russian)]. https://doi.org/10.15829/1560-4071-2020-3-3786
  101. Curb JD, Prentice RL, Bray PF, Langer RD, Van Horn L, Barnabei VM et al. Venous Thrombosis and Conjugated Equine Estrogen in Women Without a Uterus. Archives of Internal Medicine. 2006;166(7):772-80. https://doi.org/10.1001/archinte.166.7.772
  102. Blondon M, Wiggins KL, Van Hylckama Vlieg A, McKnight B, Psaty BM, Rice KM et al. Smoking, postmenopausal hormone therapy and the risk of venous thrombosis: a population‐based, case-control study. British Journal of Haematology. 2013;163(3):418-20. https://doi.org/10.1111/bjh.12508
  103. Li Y, Zhao D, Wang M, Sun J, Liu J, Qi Y et al. Association of menopause with risk of carotid artery atherosclerosis. Maturitas. 2021;143:171-7. https://doi.org/10.1016/j.maturitas.2020.10.007
  104. Schreinlechner M, Noflatscher M, Reinstadler SJ, Sommer P, Lener D, Reiser E et al. Early onset of menopause is associated with increased peripheral atherosclerotic plaque volume and progression. Atherosclerosis. 2020;297:25-31. https://doi.org/10.1016/j.atherosclerosis.2020.01.023
  105. Westendorp I, In’T Veld BA, Grobbee DE, Pols H, Meijer WT, Hofman A et al. Hormone Replacement Therapy and Peripheral Arterial Disease: The Rotterdam Study. Archives of Internal Medicine. 2000;160(16): 2498-502. https://doi.org/10.1001/archinte.160.16.2498
  106. Grady D, Herrington D, Bittner V, Blumenthal R, Davidson M, Hlatky M et al. Cardiovascular Disease Outcomes During 6.8 Years of Hormone Therapy: Heart and Estrogen/Progestin Replacement Study Follow-up (HERS II). JAMA. 2002;288(1):49-57. https://doi.org/10.1001/jama.288.1.49
  107. Rockman CB, Maldonado TS, Jacobowitz GR, Adelman MA, Riles TS. Hormone Replacement Therapy is Associated With a Decreased Prevalence of Peripheral Arterial Disease in Postmenopausal Women. Annals of Vascular Surgery. 2012;26(3):411-8. https://doi.org/10.1016/j.avsg.2011.10.012
  108. Davies RSM, Vohra RK, Bradbury AW, Adam DJ. The Impact of Hor- mone Replacement Therapy on the Pathophysiology of Peripheral Arterial Disease. European Journal of Vascular and Endovascular Surgery. 2007;34(5):569-75. https://doi.org/10.1016/j.ejvs.2007.06.002
  109. Поляков Д.C., Фомин И.В., Беленков Ю.Н., Мареев В.Ю., Агеев Ф.Т., Артемьева Е.Г. и др. Хроническая сердечная недостаточность в Российской Федерации: что изменилось за 20 лет наблюдения? Результаты исследования ЭПОХА -ХСН. Кардиология. 2021;61(4):4-14. [Polyakov D.S., Fomin I.V., Belenkov Yu.N., Mareev V.Yu., Ageev F.T., Ar temjeva E.G. et al. Chronic heart failure in the Russian Federation: what has changed over 20 years of follow-up? Results of the EPOCH-CHF study. Kardiologiia. 2021;61(4): 4-14. (in Russian)]. https://doi.org/10.18087/ cardio.2021.4.n1628
  110. Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M et al. Heart Disease and Stroke Statistics-2016 Update: A Report From the American Heart Association. Circulation. 2016;133(4):e38-360. https://doi.org/10.1161/CIR.0000000000000350
  111. Appiah D, Schreiner PJ, Demerath EW, Loehr LR, Chang PP, Folsom AR. Association of Age at Menopause With Incident Heart Failure: A Prospective Cohort Study and Meta‐Analysis. Journal of the American Heart Association. 2016;5(8):e003769. https://doi.org/10.1161/JAHA.116.003769
  112. Schierbeck LL, Rejnmark L, Tofteng CL, Stilgren L, Eiken P, Mosekilde L et al. Effect of hormone replacement therapy on cardiovascular events in re- cently postmenopausal women: randomised trial. BMJ. 2012;345:e6409. https://doi.org/10.1136/bmj.e6409
  113. Lindenfeld J, Ghali JK, Krause-Steinrauf HJ, Khan S, Adams K, Goldman S et al. Hormone replacement therapy is associated with improved survival in women with advanced heart failure. Journal of the American College of Cardiology. 2003;42(7):1238-45. https://doi.org/10.1016/ S0735-1097(03)00938- 0
  114. Liu L, Klein L, Eaton C, Panjrath G, Martin LW, Chae CU et al. Meno- pausal Hormone Therapy and Risks of First Hospitalized Heart Fail- ure and its Subtypes During the Intervention and Extended Post- intervention Follow-up of the Women’s Health Initiative Randomized Trials. Journal of Cardiac Failure. 2020;26(1):2-12. https://doi.org/10.1016/j.cardfail.2019.09.006
  115. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in col- laboration with EACTS. European Heart Journal. 2016;37(38):2893-962. https://doi.org/10.1093/eurheartj/ehw210
  116. Fang MC, Singer DE, Chang Y, Hylek EM, Henault LE, Jensvold NG et al. Gender Differences in the Risk of Ischemic Stroke and Peripheral Embolism in Atrial Fibrillation: The AnTicoagulation and Risk factors In Atrial fibrillation (ATRIA) Study. Circulation. 2005;112(12):1687-91. https://doi.org/10.1161/CIRCULATIONAHA.105.553438
  117. Dagres N, Nieuwlaat R, Vardas PE, Andresen D, Levy S, Cobbe S et al. Gender-Related Differences in Presentation, Treatment, and Outcome of Patients With Atrial Fibrillation in Europe. Journal of the American College of Cardiology. 2007;49(5):572-7. https://doi.org/10.1016/j.jacc.2006.10.047
  118. Linde C, Bongiorni MG, Birgersdotter-Green U, Curtis AB, Deisenhofer I, Furokawa T et al. Sex differences in cardiac arrhythmia: a consensus document of the European Heart Rhythm Association, endorsed by the Heart Rhythm Society and Asia Pacific Heart Rhythm Society. EP Europace. 2018;20(10):1565-1565ao. https://doi.org/10.1093/europace/euy067
  119. Thompson LE, Maddox TM, Lei L, Grunwald GK, Bradley SM, Peterson PN et al. Sex Differences in the Use of Oral Anticoagulants for Atrial Fibrillation: A Report From the National Cardiovascular Data Registry (NCDR®) PINNACLE Registry. Journal of the American Heart Association. 2017;6(7):e005801. https://doi.org/10.1161/JAHA.117.005801
  120. Lee J, Kim Y, Park H, Kim C, Cho S, Kim J. Clinical Impact of Hormone Replacement Therapy on Atrial Fibrillation in Postmenopausal Women: A Nationwide Cohort Study. Journal of Clinical Medicine. 2021;10(23):5497. https://doi.org/10.3390/jcm10235497
  121. Magnussen C, Niiranen TJ, Ojeda FM, Gianfagna F, Blankenberg S, Njolstad I et al. Sex Differences and Similarities in Atrial Fibrillation Epidemiology, Risk Factors, and Mortality in Community Cohorts: Results From the BiomarCaRE Consortium (Biomarker for Cardiovascular Risk Assessment in Europe). Circulation. 2017;136(17):1588-97. https://doi.org/10.1161/CIRCULATIONAHA.117.028981
  122. Perez MV, Wang PJ, Larson JC, Virnig BA, Cochrane B, Curb JD et al. Effects of Postmenopausal Hormone Therapy on Incident Atrial Fibrillation: The Women’s Health Initiative Randomized Controlled Trials. Circulation: Arrhythmia and Electrophysiology. 2012;5(6):1108-16. https://doi.org/10.1161/CIRCEP.112.972224
  123. Tsai W-C, Haung Y-B, Kuo H-F, Tang W-H, Hsu P-C, Su H-M et al. Hormone replacement therapy and risk of atrial fibrillation in Taiwanese menopause women: A nationwide cohort study. Scientific Reports. 2016;6(1):24132. https://doi.org/10.1038/srep24132
  124. Wong JA, Rexrode KM, Sandhu RK, Moorthy MV, Conen D, Albert CM. Menopausal age, postmenopausal hormone therapy and incident atrial fibrillation. Heart. 2017;103(24):1954-61. https://doi.org/10.1136/ heartjnl-2016-311002
  125. Fleury M-A, Clavel M-A. Sex and Race Differences in the Pathophysiology, Diagnosis, Treatment, and Outcomes of Valvular Heart Diseases. Canadian Journal of Cardiology. 2021;37(7):980-91. https://doi.org/10.1016/j.cjca.2021.02.003

Supplementary files

Supplementary Files
Action
1. JATS XML
Download
2. Приложения
Download (588KB)
Indexing metadata
3. Fig.1.

Download (183KB)
Indexing metadata
4. Приложение 1. Критерии приемлемости назначения МГТ

Download (6MB)
Indexing metadata
5. Приложение 1. продолжение

Download (6MB)
Indexing metadata
6. Приложение 1. окончание

Download (1MB)
Indexing metadata
7. Приложение 2. Алгоритм принятия решения о назначении МГТ

Download (2MB)
Indexing metadata
8. Приложение 3. Алгоритм принятия решения об отмене МГТ

Download (2MB)
Indexing metadata

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies